Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma

Publisher： Karger

E-ISSN： 1423-0232|90|6|307-312

ISSN： 0030-2414

Source： Oncology, Vol.90, Iss.6, 2016-04, pp. : 307-312

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-04 ,pp. : 249-254

Karger

Access to resources Recommend Favorite

Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701)

By  

Oncology, Vol. 84, Iss. 4, 2013-01 ,pp. : 233-239

Karger

Access to resources Recommend Favorite

mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-04 ,pp. : 280-284

Karger

Access to resources Recommend Favorite

Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer

By  

CANCER, Vol. 120, Iss. 1, 2014-01 ,pp. : 77-85

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B‐cell malignancies

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 175, Iss. 1, 2016-10 ,pp. : 55-65

John Wiley & Sons Inc

Access to resources Recommend Favorite